SUR1-mutant IPS Cell-derived Islets Recapitulate the Pathophysiology of Congenital Hyperinsulinism
Overview
Authors
Affiliations
Aims/hypothesis: Congenital hyperinsulinism caused by mutations in the K-channel-encoding genes (KHI) is a potentially life-threatening disorder of the pancreatic beta cells. No optimal medical treatment is available for patients with diazoxide-unresponsive diffuse KHI. Therefore, we aimed to create a model of KHI using patient induced pluripotent stem cell (iPSC)-derived islets.
Methods: We derived iPSCs from a patient carrying a homozygous ABCC8 mutation, which inactivates the sulfonylurea receptor 1 (SUR1) subunit of the K-channel. CRISPR-Cas9 mutation-corrected iPSCs were used as controls. Both were differentiated to stem cell-derived islet-like clusters (SC-islets) and implanted into NOD-SCID gamma mice.
Results: SUR1-mutant and -corrected iPSC lines both differentiated towards the endocrine lineage, but SUR1-mutant stem cells generated 32% more beta-like cells (SC-beta cells) (64.6% vs 49.0%, p = 0.02) and 26% fewer alpha-like cells (16.1% vs 21.8% p = 0.01). SUR1-mutant SC-beta cells were 61% more proliferative (1.23% vs 0.76%, p = 0.006), and this phenotype could be induced in SUR1-corrected cells with pharmacological K-channel inactivation. The SUR1-mutant SC-islets secreted 3.2-fold more insulin in low glucose conditions (0.0174% vs 0.0054%/min, p = 0.0021) and did not respond to K-channel-acting drugs in vitro. Mice carrying grafts of SUR1-mutant SC-islets presented with 38% lower fasting blood glucose (4.8 vs 7.7 mmol/l, p = 0.009) and their grafts failed to efficiently shut down insulin secretion during induced hypoglycaemia. Explanted SUR1-mutant grafts displayed an increase in SC-beta cell proportion and SC-beta cell nucleomegaly, which was independent of proliferation.
Conclusions/interpretation: We have created a model recapitulating the known pathophysiology of KHI both in vitro and in vivo. We have also identified a novel role for K-channel activity during human islet development. This model will enable further studies for the improved understanding and clinical management of KHI without the need for primary patient tissue.
Recent progress in modeling and treating diabetes using stem cell-derived islets.
Maestas M, Bui M, Millman J Stem Cells Transl Med. 2024; 13(10):949-958.
PMID: 39159002 PMC: 11465181. DOI: 10.1093/stcltm/szae059.
Jaffredo M, Krentz N, Champon B, Duff C, Nawaz S, Beer N Diabetes. 2024; 73(8):1255-1265.
PMID: 38985991 PMC: 11262041. DOI: 10.2337/db23-0776.
Non-invasive quantification of stem cell-derived islet graft size and composition.
Lithovius V, Lahdenpohja S, Ibrahim H, Saarimaki-Vire J, Uusitalo L, Montaser H Diabetologia. 2024; 67(9):1912-1929.
PMID: 38871836 PMC: 11410899. DOI: 10.1007/s00125-024-06194-5.
Thymidylate synthase disruption to limit cell proliferation in cell therapies.
Sartori-Maldonado R, Montaser H, Soppa I, Eurola S, Juutila J, Balaz M Mol Ther. 2024; 32(8):2535-2548.
PMID: 38867450 PMC: 11405178. DOI: 10.1016/j.ymthe.2024.06.014.
Encapsulation and immune protection for type 1 diabetes cell therapy.
Kioulaphides S, Garcia A Adv Drug Deliv Rev. 2024; 207:115205.
PMID: 38360355 PMC: 10948298. DOI: 10.1016/j.addr.2024.115205.